NL-OMON45499已完成2 期
A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia - MGL9606
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 24
研究概览
简要总结
Trial is onging in other countries
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •Patients who meet all of the following criteria will be eligible to participate in the study:
- •1. Must be willing to participate in the study and provide written informed consent;
- •2. Male and female adults *18 years of age;
- •3. Female patients of child bearing potential with negative serum pregnancy (beta human chorionic gonadotropin) test who are not breastfeeding, do not plan to become pregnant during the study, and agree to use effective birth control (ie, condoms, diaphragm, non-hormonal intrauterine device [IUD], or sexual abstinence [only if this is in line with the patient*s current lifestyle]) throughout the study and for at least 1 month after study completion; hormonal contraception (estrogens stable *3 months) and hormonal IUDs are permitted if used with a secondary birth control measure (eg, condoms); OR female patients of non-child bearing potential (ie, surgically [bilateral oophorectomy, hysterectomy, or tubal ligation] or naturally sterile [>12 consecutive months without menses]); male patients who have sexual intercourse with a female partner of child bearing potential from the first dose of study drug until 1 month after study completion must either be surgically sterile (confirmed by documented azoospermia >90 days after the procedure) OR agree to use a condom with spermicide. All male patients must agree not to donate sperm from the first dose of study drug until 1 month after study completion;
- •4. Must have a diagnosis of HeFH by genetic testing or by having met the diagnostic criteria for definite familial hypercholesterolemia outlined by the Simon Broome Register Group (Appendix C) or WHO/Dutch Lipid Network (score >8; Appendix D);
- •5. Must have a fasting LDL-C *2.6 mmol/L (100 mg/dL).
- •Any one of the following subgroups of patients with documented history of cardiovascular disease as outlined below can be included with a fasting LDL-C of * 1.8 mmol/L (70 mg/dL):
- •A) Coronary Artery Disease (CAD) including one or more of the following:
- •* Acute myocardial infarction (MI)
- •* Silent myocardial infarction
- •* Unstable angina
- •* Coronary revascularization procedure (e.g. percutaneous coronary intervention [PCI] or coronary artery bypass graft surgery [CABG])
- •* Clinically significant CAD diagnosed by invasive or non-invasive testing (such as coronary angiography, stress test using treadmill, stress echocardiography or nuclear imaging).
- •B) Previous ischemic stroke with a focal ischemic neurological deficit that persisted more than 24 hours, considered as being of atherothrombotic origin.
- •C) Peripheral arterial disease (one of the following criteria must be satisfied):
- •* Current intermittent claudication (muscle discomfort in the lower limb produced by exercise that is both reproducible and relieved by rest within 10 minutes) of presumed atherosclerotic origin together with ankle-brachial index equal to or less than 0.90 in either leg at rest, or
- •* History of intermittent claudication (muscle discomfort in the lower limb produced by exercise that is both reproducible and relieved by rest within 10 minutes) together with endovascular procedure or surgical intervention in one or both legs because of atherosclerotic disease,; or
- •* History of critical limb ischemia together with thrombolysis, endovascular procedure or surgical intervention in one or both legs because of atherosclerotic disease.
- •6. Must be on a stable or maximally tolerated dose (*4 weeks prior t
排除标准
- •Patients who meet any of the following criteria will be excluded from participation in the study:
- •1. Homozygous familial hypercholesterolemia;
- •2. Low-density lipoprotein (LDL) or plasma apheresis within 2 months prior to randomization;
- •3. New York Heart Association class III or IV heart failure, or known left ventricular ejection fraction <30%;
- •4. Uncontrolled cardiac arrhythmia, including confirmed QT interval corrected using Fridericia*s formula (QTcF) >450 msec for males and >470 msec for females at the screening electrocardiogram (ECG) assessment;
- •5. Myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass graft, or stroke within 3 months prior to randomization;
- •6. Type 1 diabetes, or newly diagnosed or uncontrolled type 2 diabetes (hemoglobin A1c [HbA1c] >8%);
- •7. History of significant alcohol consumption for a period of more than 3 consecutive months within 1 year prior to screening; Note: Significant alcohol consumption is defined as average of >20 g/day in female patients and >30 g/day in male patients;
- •8. Hyperthyroidism;
- •9. Thyroid replacement therapy;
- •10. Hypothyroidism; Note: If TSH is up to 1.5 x ULN on screening with normal free T4, one repeat test is allowed to confirm the elevation in TSH. If TSH and free T4 are normal upon repeat testing, patient may be included. Patients with a history of thyroid hormone replacement therapy or patients who have discontinued thyroid hormone replacement therapy (including thyroxine) *2 months prior to randomization may be included in the study if this criterion is met;
- •11. Evidence of chronic liver disease;
- •12. Hepatitis B, as defined by the presence of hepatitis B surface antigen;
- •13. Hepatitis C, as defined by the presence of hepatitis C virus (HCV) antibody (anti-HCV) and HCV ribonucleic acid (RNA). Patients with positive anti-HCV who test negative for HCV RNA at screening will be allowed to participate in the study;
- •14. Serum alanine aminotransferase (ALT) >1.5 × ULN (one repeat allowed);
- •15. Estimated glomerular filtration rate <60 mL/min;
- •16. Creatine kinase >3 × ULN (one repeat allowed);
- •17. History of biliary diversion;
- •18. Positive for human immunodeficiency virus infection;
- •19. History of malignant hypertension;
- •20. Systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg at screening or randomization and confirmed at an unscheduled visit;
- •21. Triglycerides >5.7 mmol/L (500 mg/dL) at screening and confirmed by repeat assessment;
- •22. Active, serious medical disease with likely life expectancy <2 years;
- •23. Active substance abuse, including inhaled or injection drugs within the year prior to screening;
- •24. Use of any excluded medications or procedures listed in Section 5.6.1;
- •25. Participation in an investigational new drug trial within the 30 days prior to randomization; or
- •26. Any other condition which, in the opinion of the Investigator, would impede compliance, hinder completion of the study, or compromise the well-being of the patient
研究者
相似试验
已完成
2 期
A Phase 2, Multi-Center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability Of CK-2127107 In Patients with Amyotrophic Lateral Sclerosis (ALS)Motor Neuron DiseaseAmyotrophic Lateral Sclerosism (ALS)10029317NL-OMON45879Cytokinetics, Inc.11
已完成
2 期
A Phase 2, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of LY3074828 in Subjects with Moderate to Severe Ulcerative Colitisinflamatory bowel disease10017969Ulcerative colitisNL-OMON46940Eli Lilly and Company7
已完成
2 期
A Phase 2b Multicentre, Randomised, Double-Blind, Active Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety and Tolerability of Zibotentan and Dapagliflozin in Patients with Chronic Kidney Disease with Estimated Glomerular Filtration Rate (eGFR) Between 20 and 60 mL/min/1.73 m2Chronic Kidney DiseaseNL-OMON52170Astra Zeneca9
招募中
2 期
A Phase IIb, 2-Arm, Randomized, Double-blind, Placebo-Controlled, Multicentre Study to Optimize Diamyd® Therapy Administered into Lymph Nodes Combined with Oral Vitamin D to Investigate the Impact on the Progression of Type 1 diabetesType 1 diabetes10018424DiabetesNL-OMON49006Diamyd Medical AB2
已完成
2 期
A Phase IIb Randomized, Double-blind, Parallel Group, Placebo- and Active-controlled Study with Double-Blind Extension to Assess the Efficacy and Safety of Vamorolone in Ambulant Boys with Duchenne Muscular Dystrophy (DMD)Duchenne Muscular DystrophyNL-OMON50318ReveraGen BioPharma, Inc.7